BeyondSpring (NASDAQ:BYSI – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49, Zacks reports.
BeyondSpring Trading Up 0.0%
Shares of BYSI opened at $0.60 on Friday. The firm has a fifty day moving average price of $0.66 and a 200-day moving average price of $1.22. The firm has a market capitalization of $24.72 million, a P/E ratio of -5.01 and a beta of -0.12. BeyondSpring has a 12-month low of $0.42 and a 12-month high of $2.44.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, BeyondSpring has an average rating of “Sell”.
Read Our Latest Analysis on BYSI
BeyondSpring Company Profile
BeyondSpring Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects. Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.
Featured Articles
- Five stocks we like better than BeyondSpring
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
